Induced PSCs (iPSCs) can be generated by expressing specific transcription factor(s) in primary somatic cells, reverting the cells back into a pluripotent state.
We are firm believers of the potential of iPSC based therapies and have invested significant efforts and resources to enable the manufacturing of cGMP grade iPSCs and differentiated cells for our customers.
We can help you address your key challenges in iPSC manufacturing and convert them into opportunities. Whether it is iPSC reprogramming or differentiation under cGMP, process control and characterization or efficient scale-up, we have a tailored solution.
As the manufacturers of the world’s first reported GMP iPSC bank, we have extensive experience in cGMP pluripotent stem cell generation and banking.
We provide a full range of iPSC manufacturing services tailored to your needs.
By combining our extensive experience in cGMP manufacture with our innovative technology, we can help you improve your efficiency and speed to market.
We have the expertise to reprogram many different cell types such as CD34+ hematopoietic progenitor cells.
Non-viral 4D-Nucleofector® Transfection Technology is a an integral part for the reprogramming of cGMP grade iPSCs. Our cGMP iPSC manufacturing platform uses the L7 cell culture system, so you can rely on a proven, established process.
Vice President, Sales and Program Management, CGT Business Unit